Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
08/25/16
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
08/17/164Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/17/164Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/04/1610-QQuarterly report which provides a continuing view of a company's financial positionQuarterly Filings Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF Download XBRL Content
08/04/168-KReport of unscheduled material events or corporate eventCurrent Reports Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
07/01/168-KReport of unscheduled material events or corporate eventCurrent Reports Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
09/21/16Pacira Pharmaceuticals Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillofacial Procedures
New research presented at AAOMS 2016 shows EXPAREL is safe and effective for pain relief following removal of wisdom teeth PARSIPPANY, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced new data regarding the benefit of EXPAREL® (bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking the official launch of the product to the oral surgeon community. EXPAREL is a local analgesic that pro... 
Printer Friendly Version
09/01/16Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
PARSIPPANY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 11:05 a.m. ET on Monday, September 12, 2016, in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” sec... 
Printer Friendly Version
08/09/16Pacira Pharmaceuticals, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference
PARSIPPANY, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the 2016 Wedbush PacGrow Healthcare Conference at 10:20 a.m. ET on Tuesday, August 16, 2016, in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section... 
Printer Friendly Version
08/04/16Pacira Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results
-- Total Net Revenues Up 18% Year-Over-Year -- -- EXPAREL® Net Product Sales Up 15% Year-Over-Year -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2016. “The second quarter marked another period of... 
Printer Friendly Version
08/01/16New Research: Opioid Addiction and Dependence After Surgery is Significantly Higher than Previously Known
Vast Majority of Surgeons Feel Pressure to Prescribe More Opioids than Patients Need Gabrielle Reece ... 
Printer Friendly Version
07/15/16Pacira Pharmaceuticals Announces Timing for Second Quarter 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., July 15, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2016 will be released before the market opens on Thursday, August 4, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, August 4, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) o... 
Printer Friendly Version
05/31/16Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference
PARSIPPANY, N.J., May 31, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2016 Healthcare Conference at 9 a.m. ET on Tuesday, June 7, 2016, in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the compan... 
Printer Friendly Version
05/03/16Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PARSIPPANY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 10, 2016, in Las Vegas. Mr. Scibetta is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” ... 
Printer Friendly Version
05/02/16Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
-- Total Net Revenues Up 12 Percent Year-Over-Year -- -- EXPAREL® Net Revenues Up 14 Percent Year-Over-Year -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., May 02, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2016. “With immense leverage across our or... 
Printer Friendly Version
04/19/16Pacira Pharmaceuticals Appoints Charles A. Reinhart III as Chief Financial Officer
PARSIPPANY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Charles A. Reinhart III to the position of Chief Financial Officer. Mr. Reinhart will be responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis and investor relations. In this position, he will succeed former Chief Financial Officer Jim Scibetta, who is currently P... 
Printer Friendly Version
>> Access Older Press Releases
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com